Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis

Drug Design, Development and Therapy

Volumn 10, Issue , 2016, Pages 1763-1770

  Gisondi, Paolo ^a   Girolomoni, Giampiero ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Apremilast; Psoriasis; Psoriasis severity; Therapy

Indexed keywords

ADALIMUMAB; APREMILAST; COLECALCIFEROL DERIVATIVE; CORTICOSTEROID; CYCLOSPORIN; DITHRANOL; ETANERCEPT; ETRETIN; FUMARIC ACID; INFLIXIMAB; METHOTREXATE; PHOSPHODIESTERASE IV; PLACEBO; SECUKINUMAB; TACROLIMUS; TAZAROTENE; USTEKINUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; THALIDOMIDE;

ABNORMAL LABORATORY RESULT; BODY SURFACE; BODY WEIGHT DISORDER; CLINICAL TRIAL (TOPIC); DERMATOLOGY LIFE QUALITY INDEX; DIARRHEA; DISEASE SEVERITY ASSESSMENT; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; HUMAN; IMMUNOMODULATION; MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS; MULTICENTER STUDY (TOPIC); NAUSEA; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOCHEMOTHERAPY; PHOTOTHERAPY; PHYSICIAN GLOBAL ASSESSMENT; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SHORT FORM 36; UPPER RESPIRATORY TRACT INFECTION; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ARTHRITIS, PSORIATIC; CHRONIC DISEASE; PATHOLOGY; SEVERITY OF ILLNESS INDEX;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, PSORIATIC; CHRONIC DISEASE; HUMANS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; THALIDOMIDE;

EID: 84971324950     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S108115     Document Type: Review

References (41)

1. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361:496–509.
2. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM; Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377–385.
3. Chandra A, Ray A, Senapati S, Chatterjee R. Genetic and epigenetic basis of psoriasis pathogenesis. Mol Immunol. 2015;64:313–323.
4. Lowes MA, Suarez-Farinas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227–255.
5. Durham LE, Kirkham BW, Taams LS. Contribution of the IL-17 pathway to psoriasis and psoriatic arthritis. Curr Rheumatol Rep. 2015;17:55.
6. Armstrong AW, Schupp C, Wu J, Bebo B. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003–2011. PLoS One. 2012;7:e52935.
7. Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70:871–881.
8. Ogdie A, Gelfand JM. Clinical risk factors for the development of psoriatic arthritis among patients with psoriasis: A review of available evidence. Curr Rheumatol Rep. 2015;17:540.
9. Gisondi P, Targher G, Zoppini G, Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51:758–764.
10. Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol. 2007;157:68–73.
11. Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013;2:e000062.
12. Davidovici B, Sattar N, Prinz J, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010;130:1785–1796.
13. Robinson A, Kardos M, Kimball AB. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J Am Acad Dermatol. 2012;66:369–375.
14. Finlay AY. Patient-reported outcome measures in psoriasis: assessing the assessments. Br J Dermatol. 2015;172:1178–1179.
15. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23 Suppl 2:1–70.
16. Scottish Intercollegiate Guidelines Network (Scottish 2010). Diagnosis and management of psoriasis and psoriatic arthritis in adults. Available from: http://sign.ac.uk/guidelines/fulltext/121/index.html. Accessed May 11, 2016.
17. Guideline on clinical investigation of medicinal products indicated for the treatment of psoriasis; 2004. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003329.pdf. Accessed May 11, 2016.
18. Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303:1–10.
19. Mrowietz U, de Jong EM, Kragballe K, et al. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2014;28:438–453.
20. van de Kerkhof PC. An update on topical therapies for mild-moderate psoriasis. Dermatol Clin. 2015;33:73–77.
21. Gisondi P, Tessari G, Di Mercurio M, Del Giglio M, Girolomoni G. The retention rate of systemic drugs in patients with chronic plaque psoriasis. Clin Dermatol. 2013;1:8–14.
22. Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol. 2005;152:861–867.
23. Gisondi P, Cazzaniga S, Chimenti S, et al. Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry. J Eur Acad Dermatol Venereol. 2013;27:e30–e41.
24. Gottlieb AB, Kalb RE, Langley RG, et al. Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies. J Drugs Dermatol. 2014;13:1441–1448.
25. Kalb RE, Fiorentino DF, Lebwohl MG, et al. Risk of serious infection with biologic and systemic treatment of psoriasis: Results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatol. 2015;151(9):961–969.
26. Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and 568 psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003–2011. JAMA Dermatol. 2013;149:1180–1185.
27. Baumer W, Hoppmann J, Rundfeldt C, Kietzmann M. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets. 2007;6:17–26.
28. Schafer PH, Parton A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal. 2014;26:2016–2029.
29. Gottlieb AB, Matheson RT, Menter A, et al. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study. J Drugs Dermatol. 2013;12:888–897.
30. Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (ESTEEM 1). J Am Acad Dermatol. 2015;73:37–49.
31. Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173(6):1387–1399.
32. Feldman S, Thaci D, Ling M, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis: pruritus and DLQI correlations at week 16 (ESTEEM 1 and 2). J Am Acad Dermatol. 2015;72(5 Suppl 1):226.
33. Yosipovitch G, Papp K, Bagel J, et al. Effects of apremilast on pruritus in patients with moderate to severe plaque psoriasis: results from the ESTEEM 1 and 2 trials. Presented at: Annual Congress of the European Academy of Dermatology and Venereology; Amsterdam, The Netherlands; October 8–12; 638; 2014.
34. Crowley J, Gooderham M, Wasel N, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with nail, scalp, and palmoplantar psoriasis 52-week results from the ESTEEM 2 trial. Presented at: 73rd Annual Meeting of the American Academy of Dermatology; March 20–24, 2015; San Francisco, CA.
35. Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73(1):37–49.
36. Reich K, Papp K, Gordon K, et al. Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis of two phase 3, randomized, controlled trials (ESTEEM 1 and 2). Presented at: Annual Congress of the European Academy of Dermatology and Venereology; October 8–12; 2014; Amsterdam, The Netherlands.
37. Reich K, Sobell J, Stevens R, Day R. Change in weight with apremilast, an oral phosphodiesterase 4 inhibitor: pooled analysis of the ESTEEM 1 and ESTEEM 2 trials. Presented at: Annual Congress of the European Academy of Dermatology and Venereology; October 8–12, 2014; Amsterdam, The Netherlands.
38. Kragballe K, van de Kerkhof PC, Gordon KB. Unmet needs in the treatment of psoriasis. Eur J Dermatol. 2014;24:523–532.
39. Menter A, Paul C, Stevens RM, Day RM, Saha K. Psychiatric disorders and depression incidence with apremilast: pooled analysis of ESTEEM 1 and ESTEEM 2 trials. Presented at: the 23rd European Academy of Dermatology and Venereology; October 8–12; 2014, Amsterdam, The Netherlands.
40. Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73:400–409.
41. Papp K, Reich K, Sobell J, et al. Two years safety of apremilast in patients with moderate to severe psoriasis: results from randomised controlled trial ESTEEM 1. Presented at: 73rd Annual Meeting of the American Academy of Dermatology; March 20–24, 2015; San Francisco, CA.